Open Label Continuation Study in Moderate to Severe Psoriasis

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate long term safety, efficacy and tolerability of ABT-874 in adults with moderate to severe psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AbbVie (prior sponsor, Abbott)

Criteria

Inclusion Criteria:

• Having participated in a preceding ABT-874 clinical trial for ABT-874

• Subject has a clinical diagnosis of moderate to severe plaque psoriasis

Exclusion Criteria:

• Subjects who prematurely discontinued in any preceding psoriasis study with ABT-874 other than protocol-required discontinuation